BAT Before Sipuleucel-T in mCRPC: Immune Priming?

Bipolar androgen therapy (BAT) given before sipuleucel‑T appears to increase the rate and magnitude of PA2024‑specific immune responses in men with metastatic castration‑resistant prostate cancer (mCRPC), compared with historical sipuleucel‑T data. The central interpretation is not that BAT by itself generates this immune response, but that BAT may prime the tumor and immune environment so sipuleucel‑T can work more consistently.

The study enrolled men with progressive mCRPC and low‑risk features (PSA < 20 ng/mL, no pain‑related opioids, no liver metastases, no prior chemotherapy) who were already on ADT. Patients received testosterone cypionate 400 mg every 4 weeks, and sipuleucel‑T began after two cycles of BAT, then continued across three standard doses. This sequencing was chosen to test BAT as an immune primer, not just a simultaneous therapy.

All 11 evaluable patients became ELISPOT‑positive to PA2024 (≥10 IFN‑γ spots), versus roughly 50% historically. T‑cell proliferation responses also reached 100%, with a mean stimulation index of about 23; no grade ≥3 toxicities occurred. These results are impressive, but they must be read carefully.

The ELISPOT response is specific to PA2024, the antigen construct used in sipuleucel‑T manufacturing and not provided by BAT alone. Mechanistically, therefore, sipuleucel‑T is the likely driver of the antigen‑specific response; BAT may simply be amplifying how many patients respond and how strongly.

This is a single‑arm trial using historical controls, with no BAT‑alone arm and no contemporaneous sipuleucel‑T‑alone cohort in the same protocol. That means the study supports a potentiation hypothesis: BAT may improve the performance of sipuleucel‑T, but not a definitive causal claim that BAT is responsible for the enhanced responses.

NOTE: in a nutshell we could say “BAT plus sipuleucel‑T looks better than historical sipuleucel‑T alone,” but we cannot isolate BAT’s role from the rest of the setup.

Early clinical signals (one partial response out of two RECIST‑evaluable patients, two PSA50 responses among 11 patients) are encouraging but far too limited to establish efficacy. The key takeaway is that BAT may be a plausible immune‑priming strategy before sipuleucel‑T in selected men with earlier mCRPC, but a randomized sipuleucel‑T ± BAT trial would be needed to confirm that sequencing advantage.

Source.